



Dear Manufacturers,

I am writing on behalf of Nemours/Alfred I. duPont Hospital for Children (340B ID# PED083300-00) (Nemours) to inform manufacturers that Nemours underwent an audit by the Health Resources and Services Administration (HRSA) of Nemours' compliance with 340B Drug Pricing Program (340B Program) requirements.

As background, Nemours qualifies for the 340B Program as a children's hospital and has participated in the 340B Program since September 2010. Nemours is located in Wilmington, Delaware.

Through the audit process, Nemours was found to have non-compliance within its 340B Program and responsible for repayment as a result of the following finding:

Nemours dispensed 340B drugs to ineligible individuals, as prohibited by 42 U.S.C. 256b(a)(5)(B).

Nemours has reversed the relevant transactions and will be notifying the affected manufacturers. Nemours has also implemented safeguards to prevent the issue from arising in the future. If you believe that Nemours owes you repayment for the violations described in this letter and have not yet heard from Nemours, or if you have any questions or comments regarding the violations described in this letter, please contact Robert Mullen, Director of Pharmacy, 1600 Rockland Road Wilmington, DE 19803, 302-651-5711.

Sincerely,

William Britton
Chief Financial Officer
Nemours/Alfred I. duPont Hospital for Children
1600 Rockland Road
Wilmington, DE 19803